When Guidelines Meet Reality: The Combined Impact of Assay Variability and Prescribing Differences on TSH Management in Thyroid Cancer
Guidelines are not uniformly applied in thyroxine dosing for DTC patients. TSH immunoassays have achieved adequate analytical performance. The focus must now shift toward addressing clinical, educational, and systemic factors that prevent optimal levothyroxine management.
Authors
- Lilla Bonanno (ORCID: https://orcid.org/0000-0002-0282-405X)
- Petra Petranović Ovčariček (ORCID: https://orcid.org/0000-0003-1946-2128)
- Federica D’Aurizio (ORCID: https://orcid.org/0000-0003-2311-859X)
- Angela Alibrandi (ORCID: https://orcid.org/0000-0001-6695-151X)
- Luca Giovanella (ORCID: https://orcid.org/0000-0003-0230-0974)
- Mauro Imperiali
- Alfredo Campennì (ORCID: https://orcid.org/0000-0002-0177-939X)
- Rosaria Maddalena Ruggeri (ORCID: https://orcid.org/0000-0001-8899-684X)
Institutions
- University of Messina (IT)
- University of Udine (IT)
- University of Zagreb (HR)
- University Hospital of Zurich (CH)
- Labormedizinische Zentrum Dr Risch (Switzerland) (CH)
- Clinica Luganese Moncucco (CH)
- Centro Neurolesi Bonino Pulejo (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-07
- DOI
- https://doi.org/10.3390/cancers17243912
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00